Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

40 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
Wachtell K, Hornestam B, Lehto M, Slotwiner DJ, Gerdts E, Olsen MH, Aurup P, Dahlöf B, Ibsen H, Julius S, Kjeldsen SE, Lindholm LH, Nieminen MS, Rokkedal J, Devereux RB. Wachtell K, et al. Among authors: rokkedal j. J Am Coll Cardiol. 2005 Mar 1;45(5):705-11. doi: 10.1016/j.jacc.2004.06.080. J Am Coll Cardiol. 2005. PMID: 15734614 Free article. Clinical Trial.
In-treatment midwall and endocardial fractional shortening predict cardiovascular outcome in hypertensive patients with preserved baseline systolic ventricular function: the Losartan Intervention For Endpoint reduction study.
Wachtell K, Gerdts E, Palmieri V, Olsen MH, Nieminen MS, Papademetriou V, Boman K, Dahlöf B, Aurigemma GP, Rokkedal JE, Devereux RB. Wachtell K, et al. Among authors: rokkedal je. J Hypertens. 2010 Jul;28(7):1541-6. doi: 10.1097/HJH.0b013e328339f943. J Hypertens. 2010. PMID: 20410835 Clinical Trial.
In-treatment reduced left atrial diameter during antihypertensive treatment is associated with reduced new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy: The LIFE Study.
Wachtell K, Gerdts E, Aurigemma GP, Boman K, Dahlöf B, Nieminen MS, Olsen MH, Okin PM, Palmieri V, Rokkedal JE, Devereux RB. Wachtell K, et al. Among authors: rokkedal je. Blood Press. 2010 Jun;19(3):169-75. doi: 10.3109/08037051.2010.481811. Blood Press. 2010. PMID: 20438307
Prognostic significance of left ventricular diastolic dysfunction in patients with left ventricular hypertrophy and systemic hypertension (the LIFE Study).
Wachtell K, Palmieri V, Gerdts E, Bella JN, Aurigemma GP, Papademetriou V, Dahlöf B, Aalto T, Ibsen H, Rokkedal JE, Devereux RB. Wachtell K, et al. Among authors: rokkedal je. Am J Cardiol. 2010 Oct 1;106(7):999-1005. doi: 10.1016/j.amjcard.2010.05.032. Am J Cardiol. 2010. PMID: 20854964 Clinical Trial.
Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial.
Devereux RB, Dahlöf B, Gerdts E, Boman K, Nieminen MS, Papademetriou V, Rokkedal J, Harris KE, Edelman JM, Wachtell K. Devereux RB, et al. Among authors: rokkedal j. Circulation. 2004 Sep 14;110(11):1456-62. doi: 10.1161/01.CIR.0000141573.44737.5A. Epub 2004 Aug 23. Circulation. 2004. PMID: 15326072 Clinical Trial.
40 results